Although BPC-157 has been studied primarily for human applications, growing interest in its use in horses is based on its remarkable ability to speed up the healing process in tissues such as tendons, ligaments, joints, and muscles
Similarly, cagrilintide is being developed by Novo Nordisk , primarily as part of the CagriSema combination, with regulatory submissions anticipated once Phase 3 data are fully analysed and published
Biofabrication of human articular cartilage: a path towards the development of a clinical treatment
Treatment response durations varied, with Payne et al
This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 269,00 per year only 22,42 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF